American Association for Cancer Research
Browse

sorry, we can't preview this file

23266066cir170475-sup-188530_2_supp_4699165_p7650m.docx (1.71 MB)

Supplementary Data from The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma

Download (1.71 MB)
journal contribution
posted on 2023-04-03, 23:27 authored by Rana R. McKay, Dominick Bossé, Wanling Xie, Stephanie A.M. Wankowicz, Abdallah Flaifel, Raphael Brandao, Aly-Khan A. Lalani, Dylan J. Martini, Xiao X. Wei, David A. Braun, Eliezer Van Allen, Daniel Castellano, Guillermo De Velasco, J. Connor Wells, Daniel Y. Heng, Andre P. Fay, Fabio A. Schutz, JoAnn Hsu, Sumanta K. Pal, Jae Lyun Lee, James J. Hsieh, Lauren C. Harshman, Sabina Signoretti, Robert J. Motzer, Darren Feldman, Toni K. Choueiri

Includes: Table 1S. Baseline patient and disease characteristics. Table 2S. Tumor mutation burden status. Table 3S. PDL1 expression data. Figure 1S. Overall survival for the total cohort.

Funding

Harvard Cancer Center Kidney Cancer SPORE

Memorial Sloan Kettering Cancer Center

History

ARTICLE ABSTRACT

Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non–clear cell RCC (nccRCC) or patients with sarcomatoid/rhabdoid differentiation are limited. In this multicenter analysis, we explored the efficacy of PD-1/PD-L1 inhibitors in patients with nccRCC or sarcomatoid/rhabdoid differentiation. Baseline and follow-up demographic, clinical, treatment, and radiographic data were collected. The primary endpoint was objective response rate. Secondary endpoints include time-to-treatment failure (TTF), overall survival (OS), and biomarker correlates. Forty-three patients were included: papillary (n = 14; 33%), chromophobe (n = 10; 23%), unclassified (n = 9; 21%), translocation (n = 3; 7%), and ccRCC with sarcomatoid differentiation (n = 7, 16%). Of those 43 patients, 11 patients (26%) had sarcomatoid and/or rhabdoid differentiation (n = 7 with ccRCC; n = 4 nccRCC). Overall, 8 patients (19%) objectively responded, including 4 patients (13%) who received PD-1/PD-L1 monotherapy. Responses were observed in patients with ccRCC with sarcomatoid and/or rhabdoid differentiation (n = 3/7, 43%), translocation RCC (n = 1/3, 33%), and papillary RCC (n = 4/14, 29%). The median TTF was 4.0 months [95% confidence interval (CI), 2.8–5.5] and median OS was 12.9 months (95% CI, 7.4–not reached). No specific genomic alteration was associated with clinical benefit. Modest antitumor activity for PD-1/PD-L1–blocking agents was observed in some patients with nccRCC. Further prospective studies are warranted to investigate the efficacy of PD-1/PD-L1 blockade in this heterogeneous patient population. Cancer Immunol Res; 6(7); 758–65. ©2018 AACR.

Usage metrics

    Cancer Immunology Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC